GMED
Research Snapshot
Static fundamentals, valuation context, and investor signals for GLOBUS MEDICAL, INC. (GMED).
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
11.8%
ROIC, 20.0% FCF margin
Growth
30.1%
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 4.3x current ratio
Superinvestors
2
Top: Lee Ainslie (0.0%)
Strengths to research
- Revenue compounded at 30.1% over five years.
- Free cash flow compounded at 34.2% over five years.
- Free cash flow margin is healthy at 20.0%.
- Debt/equity looks manageable at 0.0x.
Watchouts
- Valuation multiples are limited or unavailable.
Annual data: 10 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for GMED.
Grade C
55
/ 100
Financial Charts
No financial data available for GMED (annual).
2 superinvestors own GMED
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Lee Ainslie Maverick Capital | 15,660 | $1M | 0.02% | 0.0% |
| Ruane Cunniff Sequoia Fund | 6,008 | $518,000 | 0.01% | 0.0% |